HURA

$2.08

Market ClosedAs of Mar 17, 8:00 PM UTC

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.08
Potential Upside
5%
Whystock Fair Value$2.18
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome prim...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$117.47M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-418.06%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.35

Recent News

Simply Wall St.
Aug 11, 2025

TuHURA Biosciences, Inc.'s (NASDAQ:HURA) last week's 11% decline must have disappointed retail investors who have a significant stake

NasdaqCM:HURA 1 Year Share Price vs Fair Value Explore TuHURA Biosciences's Fair Values from the Community and select...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MT Newswires
Apr 28, 2025

TuHURA Biosciences Reports Cancer Immunotherapy Safe, Well Tolerated in Clinical Trial

TuHURA Biosciences (HURA) said Monday that updated results from Kineta's VISTA-101, a Phase I/II fir

BEARISH
Negative press. News cycle fixated on risk factors or misses.
Insider Monkey
Apr 18, 2025

Is TuHURA Biosciences, Inc. (HURA) the Best Rising Penny Stock to Buy According to Analysts?

We recently published a list of the 10 Best Rising Penny Stocks to Buy According to Analysts. In this article, we are going to take a look at where TuHURA Biosciences, Inc. (NASDAQ:HURA) stands against other best rising penny stocks to buy according to analysts. Small-Cap Performance in Q1 2025 The start of 2025 was […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Apr 2, 2025

Is TuHURA Biosciences (NASDAQ:HURA) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.